← Latest news 
Sun Pharma bids $13 billion for Organon to leap into global branded drugs
Business
Published on 24 April 2026
The offer could redraw Organon’s future overnight
Sun Pharmaceutical has made a bold $13 billion bid for US firm Organon & Co., signaling its biggest push to shift from generics toward branded and innovative medicines. Sun is competing with other bidders for Organon, and a successful deal would effectively merge Organon into Sun Pharma, reshaping its global ambitions.
- Sun Pharma’s $13 billion bid is its largest ever for Organon
- The goal is to pivot toward branded and innovative medicines
- Sun is not the only bidder for Organon in the US
- A deal would merge Organon into Sun Pharma
Read the full story at The Economic Times
This summarization was done by Beige for a story published on 
The Economic Times